Skip to main content

Table 4 Comparison of general AEs for dabrafenib plus trametinib versus vemurafenib plus cobimetinib

From: Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients

 

Incidence, number (%)

ITC results

COMBI-v

coBRIM

AE type

D + T (n = 350)

V (n = 349)

V (n = 246)

V + C (n = 247)

RR

LCI

UCI

p value

Any AE

345(98.6)

345(98.9)

240(97.6)

244(98.8)

0.98

0.96

1.01

0.3078

Any serious AE

151(43.1)

136(39.0)

64(26.0)

85(34.4)

0.84

0.60

1.16

0.2835

Any treatment-related AE

320(91.4)

342(98.0)

232(94.3)

237(96.0)

0.92

0.87

0.97

0.0015

AE leading to death

4(1.1)

4(1.2)

3(1.2)

5(2.0)

0.60

0.08

4.35

0.6137

Any grade ≥3 AE

199 (56.9)

232 (66.5)

146 (59.4)

176 (71.3)

0.71

0.60

0.85

0.0002

Any dose interruptions/modifications

192(54.9)

197(56.5)

87(35.4)

110(44.5)

0.77

0.60

1.00

0.0471

Discontinuation due to AE

55(15.7)

48(13.8)

20(8.1)

37(15.0)

0.62

0.33

1.16

0.1350

  1. AE adverse event, CI confidence interval, D + T dabrafenib plus trametinib, ITC indirect treatment comparison, RR risk ratio, LCI lower 95% CI, UCI upper 95% CI, V vemurafenib, V + C vemurafenib plus cobimetinib